Introduction
Pancreatic cancer is highly aggressive and is a leading cause of cancer death with a 5-year survival rate of less than 5%. 1 Currently, there is no effective treatment for this disease; surgical resection is only applicable to a small proportion of patients with a marginal effect on the overall survival rate, and chemotherapy and radiation also have very limited effects on patient's survival. 2 Therefore, there is a need for new approaches to treat such an aggressive disease. Gene therapy in which a particular gene is transduced to control the growth and metastatic ability of cancer cells may be a promising alternative approach for the management of pancreatic cancer. 3 The Hedgehog (Hh) signaling pathway is crucial in the growth and patterning during embryonic development. [4] [5] [6] [7] Up to now, studies have shown that the Hh ligand family (include Shh, Dhh and Ihh) are present in mammals. 8 Interestingly, Hh signaling is mediated via a series of inhibitory steps. 9 After secretion, the diffusion of all three Hh ligands is limited by binding to the Hip1, PTCH1 and PTCH2 transmembrane receptors, all of which are expressed on Hh-responsive cells. In the absence of binding to Hh ligands, PTCH1 holds Smo, a seven-pass transmembrane protein, in an inactive state and thus inhibits signaling to downstream genes. Upon binding to Hh ligands, the inhibition of Smo is released and signaling is transduced, leading to the activation of target genes by the GLi family of transcription factors. [10] [11] [12] [13] [14] [15] PTCH1 is one of the target genes whose expression is regulated by its alternative promoters and mainly by a single functional GLi-binding site, thus generating a negative feedback loop, which plays an important role in Hh pathway regulation. 8, 16 Therefore, expression of PTCH1, Smo and GLi is presumed to be the markers of the Hh pathway activation.
Recent data have shown an association between the Hh pathway activation and the cancer formation and maintenance. 9, 17 Constitutive activation of the Hh pathway has been found in several types of tumors. The ligand-independent activation of the Hh pathway caused by the mutations in PTCH1 or Smo results in the tumorigenesis of brain, skin and muscles, whereas ligand-dependent activation of Hh pathway is demonstrated in small-cell lung carcinoma and tumors in the digestive tract such as esophageal carcinoma, gastric carcinoma and pancreatic carcinoma. 18 In fact, it has been shown that the plant-derived teratogenic steroidal alkaloid cyclopamine inhibits the Hh pathway by antagonizing Smo and suppresses the growth of cancer cells both in vitro and in vivo. 19, 20 Observationally, the misregulation of the Hh pathway, that is, all Hh components (Shh, PTCH1 and Smo) are markedly over-expressed, is thought as an early and late important mediator of human pancreatic cancer tumorigenesis. These suggest that targeting at the components of Hh signaling pathway via the transgenic methods may provide a new therapeutic strategy for the treatment of human pancreatic cancer (HPC). 21 In this study, we applied an antisense strategy in which the transcription of the antisense Smo (SAS) was under the control of the PTCH1 gene promoter (ptch/p) delivered by an adenoviral vector. It was expected that such a strategy specifically blocks the translation of Smo mRNA into protein in the HPC cells where the Hh pathway is activated.
Results
Identification of the expression of Hh signal components in HPC cell lines HPC cell lines (PaTu8988, Panc-1, SW1990, BxPC3 and CFPAC) were screened for the expression of PTCH1, Smo and GLi1 using reverse transcriptase-polymerase chain reaction (RT-PCR) (Figure 1 ). PTCH1 and Smo and GLi1 genes were all expressed in PaTu8988, Panc-1 and BxPC3 cell lines, and both PTCH1 and GLi1 were expressed in SW1990 cell line, whereas only GLi1 was expressed in CFPAC cell line. These indicate that Hh pathway activity is common in HPC cell lines, but the present profile of the components of Hh pathway is various in different cell lines.
HPC cell lines expressing different levels of ptch/p-LacZ gene
To determine whether ptch/p was transactivated in HPC cells, the LacZ expression driven under the PTCH1 or CMV (cytomegalovirus) promoter was assayed in five HPC cell lines by b-galactosidase enzyme activity detection. The infection of Ad-CMV-LacZ resulted in a marked increase of LacZ expression in all cell lines, whereas Ad-ptch/p-LacZ was expressed only in PaTu8988, Panc-1, BxPC3 and SW1990 cells but not in CFPAC cell line, and the CMV promoter exhibited a stronger effect than the PTCH1 promoter ( Figure 2 ). These results suggest that the PTCH1 promoter can drive downstream gene to express specifically in the HPC cell lines, where both PTCH1 and GLi1 genes are inherently expressed ( Figure 1 ).
Effect of Ad-ptch/p-SAS and Ad-CMV-SAS on the growth of HPC cells in vitro
In order to analyze the effect of SAS on the inhibitory tumor cell growth, the cell viability of five HPC cell lines was detected after infected by Ad-ptch/p-SAS or Ad-CMV-SAS at 100 MOI (multiplicity of infection). The results were shown in Figure 3 . There was no significant difference of the proliferation among the uninfected cells for all cell lines studied. The cells infected with either Ad-CMV-SAS or Ad-ptch/p-SAS showed a similar effect of growth inhibition on PaTu8988, Panc-1 and BxPC3, where all three components of the Hh signal pathway (PTCH1, Smo and GLi1) were expressed. However, either Ad-CMV-SAS or Ad-ptch/p-SAS had no inhibitory effect on the growth in SW1990 and CFPAC cell lines where Smo gene transcription was not detected by RT-PCR ( Figure 1) . Moreover, the growth inhibition ability of SAS driven by the PTCH1 promoter was as vigorous as that of the CMV promoter, although the CMV promoter had a stronger effect than the PTCH1 promoter according to the above-mentioned LacZ expression experiment (Figure 2) .
The flow cytometry showed that the number of apoptotic cells, presented in the lower right quadrants (fluorescein isothiocynate (FITC)-Annexin V positive and propidium iodide (PI) negative), increased with time in the infected cells whose proliferation were inhibited. Figure 4 showed the typical fluorescence-activated cell sorting (FACS) data obtained at 0, 24 and 48 h after the Ad-ptch/p-SAS infection in BxPC3 cells. Furthermore, Western blotting showed that the expression of Smo protein in BxPC3 cells at 48 h after the infection of Ad-CMV-SAS or Ad-ptch/p-SAS was significantly decreased 3 ) were infected with Ad-ptch/p-LacZ, or Ad-CMV-LacZ at 100 MOI for 1 h at 371C. After 36 h, the infected cells were washed and collected. The b-galactosidase activity from each transfection was determined using a luminometer and normalized by protein levels. Data are represented in light units and adjusted for protein content (n ¼ 6). Smo antisense therapy for pancreatic cancer J Gao et al
Effect of Ad-ptch/p-SAS on the growth of pancreatic cancer BxPC3 cells in vivo
Growth experiments were conducted in vivo to assess whether the SAS derived by ptch/p could inhibit HPC growth. We tried to treat the BxPC3 (human pancreatic ductal adenocarcinoma cells) tumor xenografts with the adenoviral infections in nude mice. As shown in Figures  6 and 7a, the tumors in mice that received Ad-ptch/ p-SAS treatment grew slower than those in mice treated with Ad-ptch/p-LacZ or without treatment. Ad-ptch/ p-SAS inhibited tumor growth on day 28 by 77.5 and 75.2% in tumor volume compared with the phosphatebuffered saline (PBS) and Ad-ptch/p-LacZ, respectively. The Ad-ptch/p-LacZ-treated tumors showed a slight growth inhibition in the early phase compared with the PBS-treated tumors. With hematoxylin and eosin (H&E) staining, apoptotic cells were characterized by those cardinal features, including a condensed, shrunken eosinophilic cytoplasm and prominent nuclear alteration (Figure 7b ). More apoptotic cells presented in mice treated with Ad-ptch/p-SAS than in those treated with Ad-ptch/p-LacZ, or PBS ( Figure 7) . Although the cardinal features of apoptotic cells in H&E staining section is sensitive, observer-dependent and tedious, 22 the appearance of the typical morphologic features in the present study implied that the inhibition of the growth of pancreatic cancer cells by Ad-ptch/p-SAS in vivo mainly contributed to apoptosis, which was also confirmed by the flow cytometry in vitro. Throughout these experiments, there was no significant difference in body weight gain and there was no illness or treatment-related death (data not shown).
Discussion
Recent observations that uncontrolled activation of the Hh signaling pathway results in distinct cancers of the brain, muscle and skin have received significant attention. 9 More importantly, specific inhibition of this pathway blocks tumor growth, indicating that active Hh signaling is essential for tumor survival. Many Hh signaling inhibitors have been reported to effectively block Hh pathway activity and most of them target Smo. Although there is a common consensus that the Hh pathway is activated and its components are expressed in some adult stem cells, 23 recent studies have shown that the expression profiles of some components such as PTCH1 gene are different between tumorous and normal tissues. 16, 24 Therefore, treatment strategy by targeting the Hh pathway, such as antagonizing Smo in this study, needs to be selectively performed in specific tumor cell types.
Some cell-specific promoters, such as insulin promoter and survivin promoter, have been used to drive the transgene in the HPC cells. 25, 26 In this study, we used the PTCH1 gene promoter to construct a transgenic vector. It has been recently reported that there are seven alternative first exons of PTCH1 (exon 1a, exon 1a 0 , exon 1b, exon 1c, exon 1c 0 , exon 1d and exon 1e), which are differentially regulated by independent promoters in various normal and tumor tissues. 16 Normally, both exon 1d and exon 1e (exon 1 and exon 1A) are detected in all tissues such as thymus, prostate, spleen, testis, colon, ovary and intestine, whereas exon 1b (exon1B) is expressed in testis and at significantly lower levels in spleen, colon and ovary. However, in nodular basal cell carcinoma (BCC) and adjacent normal tissues, the levels of exon 1d and exon 1e transcripts appear similar in both tumor and normal tissues, whereas relative transcription levels of exon 1b are increased in tumors. 24 Although it has been presumed that three putative GLi-binding sites (GLi-BS1, GLi-BS2 and GLi-BS3) dispersed over in the PTCH1 gene regulation sequence (7.5 kb) be involved in GLi-mediated PTCH expression, exon 1b transcript that mainly exists in tumor tissues is principally subjected to GLi-BS1 activity, and this single functional GLi-binding site activity mediated by the Hh signal pathway supplies the transcriptional activation of PTCH1 gene. 16, 27 More- Smo antisense therapy for pancreatic cancer J Gao et al over, the aberrant Hh signaling pathway, as observed in this study, has also been reported in HPC cell lines and tissues. 20, 21 Thus, we cloned one putative PTCH1 promoter (1372 bp), which contains the GLi-BS1-binding site (TGGGTGGTC), and used this promoter to drive selectively the expression of the transgene SAS in the HPC cells. We observed that the PTCH1 promoter had the capability to drive the downstream gene (LacZ) to transcribe in HPC PaTu8988, Panc-1, BxPC3 and SW1990 cell lines, where the GLi1 was present. This coincides with the previous reports that the activation of the PTCH1 promoter was associated with the presence of GLi1. 27 However, it is noticed that when the GLi1 gene was detected in CFPAC cells, the transgene PTCH1 promoter cannot be activated. We propose that this probably ascribes to the outcomes of the interaction of transactivators with promoters. Figure 1 shows that many components of the Hh pathway are aberrantly expressed in HPC cell lines with differential cell type-specific expression profiles, for example, PTCH1 gene is not expressed in CFPAC, and Smo is not expressed in both SW1990 and CFPAC. This results imply that the transactivating activity of each promoter of Hh component genes is different in the various HPC cell lines, which is confirmed by the evidence that in cell lines with inherent PTCH1 expression such as PaTu8988, Panc-1 and BxPC3, the PTCH1 promoter is transactivated, driving the LacZ gene to express specifically, whereas in CFPAC cells where PTCH1 does not inherently express, LacZ gene driven by the PTCH1 promoter cannot express (Figure 2) . With regard to the underlying mechanism for inactivation of the PTCH1 promoter in CFPAC cells, we presume that in the course of PTCH1 promoter activation, in addition to GLi1, which is a capital transcriptional activator, other unidentified activators are also required.
According to the observation that the expression of PTCH1 gene was detected by RT-PCR in all cell lines except CFPAC1 in the present study, we consider that the inherent expression of PTCH1 gene in the target cells is a definitive marker for its ability to transactivate the PTCH1 promoter. Therefore, the PTCH1 promoter can exert its cell-specific action only in the HPC cells whose genomic PTCH gene can be activated. Additionally, Smo is expressed in most HPC cell lines, as shown in Figure 1 , which coincides with many previous studies. 20, 21 We propose that under the control of PTCH1 promoter, the transgene SAS in HPC cells exhibits a tumor-specific inhibitory effect on cell growth, thus avoiding toxic side effects on normal cells.
The clinical applicability of oligonucleotide or liposomal approaches seems to be limited, because of their relatively low efficiency of gene transduction, slow uptake into cells and physiological instability. 28, 29 Among various vector systems that have been reported to date, the adenoviral vector seems to be the most clinically useful vector because of its simplicity in preparation and high efficiency of gene transduction regardless of tissue type and cell cycle. The AdEasy system was developed by He et al. 30 in 1998 as a fast and alternative to traditional systems for the production of recombinant adenoviral vectors. In the course of constructing the recombinant vector, we modified the pShuttle vector by the addition of the PTCH1 promoter and a synthetic polyadenylation signal in the multi-clone site (MCS) in pShuttle. Our experiment showed that this modified vector was particularly suitable for the development of an effective, specific antisense gene therapy for HPC.
Slight toxicity of control Ad-CMV-LacZ to some cell lines has been reported, and it is most likely caused by virus toxicity itself and LacZ gene products. 29, 31 Although we previously reported highly efficient gene transduction into HPC cells by the AdEasy system, 32 a non-toxic Smo antisense therapy for pancreatic cancer J Gao et al virus dose must be selected by comparing with the same dose of control virus. In the present study, we observed that the dosage of 100 MOI for all HPC cell lines was sufficient to achieve highly efficient gene transduction without obvious cell toxicity. In the future, it would be a clinical practice that multiple intratumoral injection of adenoviruses. Owing to the rapid development of endoscopic techniques such as endoscopic ultrasonography and laparoscopic ultrasonography, many new therapeutic strategies have been applied in clinical practice. Novel endoscopic resection and ablative techniques provide more therapeutic choices for premalignant and malignant pancreatic diseases. Currently, endoscopy plays an important role in the diagnosis of pancreatic cancer. Moreover, injection of chemical drugs or implantation of radiating particles into the tumor mass guided by endoscopic ultrasonography or laparoscopic ultrasonography has been used to treat pancreatic cancer. Therefore, it is feasible and convenient that multiple intratumoral injection of adenoviruses is guided by endoscopic ultrasonography or laparoscopic ultrasonography for pancreatic cancer gene therapy, although further evaluation is required.
In conclusion, transfection of HPC cells with the antisense Smo under the control of the PTCH1 gene promoter (ptch/p) delivered by an adenoviral vector increases apoptosis in vitro and decreases tumor growth in an in vivo tumor xenograft model. This inhibitory effect on the tumor growth is dependent on the inherent existence of Smo expression in the cells. In addition, this inhibitory effect is more specific on the cells where PTCH1, Smo and GLi1 genes are expressed, thereby avoiding side effects on normal cells. This approach targeting Smo may provide a novel method for the treatment of pancreatic cancer alone or in combination with other agents. Further studies are warranted to determine the expression prevalence and pattern of the main components of the Hh pathway including Shh, PTCH1, Smo and Gli1 in clinical HPC tissues, in order to further the preclinical development of therapies through the Hh pathway, particularly for pancreatic cancer for which few therapeutic options are available.
Materials and methods

Cell culture
HPC cell lines (Panc-1, SW1990 and PaTu8988) and adenovirus E1a-transformed human embryonic kidney cell line (293) were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) at 371C with 5% CO 2 . HPC cell lines (BxPC3 and CFPAC) were cultured in DMEM with 10% FBS and 2.5% horse serum at 371C with 5% CO 2 . Panc-1, SW1990, BxPC3 and CFPAC cells were purchased from the American Type Culture Collection. PaTu8988 was obtained from Dr HP Elsasser (Phillips University, Marburg, Germany). The 293 cell line was purchased from the Microbix (Toronto, ON, Canada).
Clone of the PTCH1 promoter and modification of the pShuttle vector of the AdEasy XL adenoviral vector system DNA was isolated from human pancreatic cell lines SW1990 by the standard phenol/chloroform extraction method. The genomic region of PTCH1 5 0 -untranslated region ranging from À1322 to +50 bp (relative to the transcriptional start site for exon1b) 16, 24 was amplified by using the sense primer (5 0 -GCGGTACCCACGTTTATA GAACACTGACTCCTTCAAAC-3 0 ) and antisense primer (5 0 -GCCTCGAGGCCGAGCGAGCCTGTCCTT-3 0 ). The sense and antisense primers contained a KpnI and XhoI site, respectively, at the 5 0 and 3 0 ends (underline) for subcloning purposes. The PCR was carried out in a 50 ml reaction volume by using LA Taq with GC Buffer (TaKaRa, Tokyo, Japan) according to the manufacturer's instruction. PCR was run for 35 cycles of denaturation at 941C for 1 min, annealing at 601C for 1 min and extension at 721C for 3 min. The PCR-amplified fragment was purified from the agarose gel using QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany).
The process of pShuttle vector modification included two steps. Firstly, a synthetic polyadenylation signal (polyA, 5 0 -GCCGTCGACAATAAAATATCTTTATTTT CATTACATCTGTGTGTTGGTTTTTTGTGTGAGATCTC CG-3 0 ) which contained the SalI and BglII sites, respectively, at its 5 0 and 3 0 terminal (underline) was added into the MCS of the pShuttle vector (Stratagene, La Jolla, CA, USA). Then, the purified PCR-amplified PTCH1 promoter was inserted into the KpnI and XhoI sites of the polyA-modified pShuttle vector to generate pShuttleptch/p. The authenticity of the sequence of the PTCH1 promoter and the construct of pShuttle-ptch/p were confirmed by DNA sequencing.
RT-PCR analysis
Total RNA was extracted from all pancreatic cancer cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. The RNA solution was treated with DNaseI to remove the trace amount of genomic DNA contamination by using DNAse RQ1 (Promega, Madison, WI, USA). One microgram of RNA of each cell line was converted to cDNA using primer p(DT)15 for cDNA synthesis and Expand Reverse Transcriptase (Roche Diagnostics, Mannheim, Germany) in a total volume of 50 ml. Four independent PCR reactions for each primer pair were performed using 5 ml of the synthesized cDNA/reaction for 35 cycles of 30 s each at 941C, 591C (PTCH1 and GLi1) or 551C (Smo and b-actin) and 721C. The following oligonucleotides were used for gene-specific amplification:
0 ; GLi1 -sense, TGCCTTGTACCCTCCT CCCGAA, GLi1 -antisense, GCGATCTGTGATGGATG AGATTCCC; and b-actin -sense, 5
0 -GCATTGTTACAG GAAGTCCCTTGCC-3 0 , b-actin -antisense, 5 0 -ACCCAC TCCCAGGGAGACCAAAAG-3 0 . The Smo sense and antisense primers contained SalI and XhoI site, respectively, at its 5 0 and 3 0 ends (underline), which were used for subcloning Smo into the above-modified adenovirus shuttle vector in the antisense orientation to obtain Smo antisense mRNA.
Preparation of adenovirus vectors
In this experiment, we constructed four recombinant adenovirus vectors (Ad): Ad-ptch/p-SAS, Ad-ptch/ . These recombinant adenoviruses were propagated and purified in 293 cells to obtain the viral stocks (stored at À801C). The viral titers of the viral stocks were determined by a modified end point cytopathic effect assay as described previously.
32,33
Infection of recombinant adenoviruses and detection of LacZ gene expression Panc-1, SW1990, PaTu8988, BxPC3 and CFPAC cell lines were plated into a 96-well microtiter plate at a density of 1 Â 10 3 cells/well. A virus dose that exhibits almost 100% transduction rate without any cell toxicity was determined individually for each cell line by Ad-CMV-LacZ transduction assay, resulting in an MOI of 100 for all pancreatic cancer cell lines. Then, cells were infected by the recombinant adenovirus (Adptch/p-LacZ and Ad-CMV-LacZ) at the 100 MOI for 1 h at 371C. At 36 h after the infection, the cells were washed twice with PBS and fixed by 0.5% glutaraldehyde for 15 min. After removal of the fixation solution, cells were washed three times with PBS and stained with X-gal solution (containing 1 M MgCl 2 , 5M 4-(2-hydroxyethyl)-1-piperazineethyl-sulfonic acid (pH 7.3), 30 mM potassium ferricyanide, 30 mM potassium ferrocyanide and 2% X-gal). Cells were then incubated at 371C for 6-24 h for color development.
For the b-galactosidase reporter assay, cells were washed twice in PBS and collected into a 1.5 ml tube. Cells were then added in 150 ml of lysis buffer. A 20 ml portion of each sample was placed in a test tube and incubated with substrate for 40 min (Tropix, Bedford, MA, USA). The assay was carried out in triplicate, and the b-galactosidase activity was measured using a luminometer. Protein levels were determined using the Bradford's protein reagent (Sigma, St Louis, MO, USA), and bovine serum albumin was used as a standard.
Results were represented in light units and adjusted for the protein content.
In vitro growth assay and FACS analysis of apoptotic cells
Human pancreatic cell lines were plated into a 96-well microtiter plate at a density of 1 Â 10 3 cells/well. After the cells were incubated with the recombinant adenovirus at the MOI of 100 for 1 h at 371C, fresh growth medium was added. During 1-4 days of incubation, the cellular proliferation was measured by 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay as we reported previously. 31 FACS analysis of apoptotic cells was performed after the recombinant adenovirus infection for periods of 0, 24 and 48 h. Apoptotic cells were determined using a previously described method. 34 Cells were stained with Annexin V-FITC and PI according to the manufacturer's instructions (R&D System, Abingdon, UK) and analyzed by a flow cytometer (Becton Dickinson, Fullerton, CA, USA). At least 10 4 cells were counted.
Western blot analysis
Immunoblotting analysis was performed as described previously. 32 Briefly, culture cells were processed in a buffer containing 2% sodium dodecyl sulfate (SDS), 62.5 mM Tris-HCl (pH 6.8), 100 mM dithiothreitol and 10% glycerol, applied for SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose membrane. Protein signals were visualized using the following antibodies: goat anti-Smo antibodies (C-17; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and horseradish peroxidase-conjugated anti-goat antibodies (Sigma, St Louis, MO, USA). Signals were visualized by Molecular Imager FX (Bio-Rad Laboratories Inc., Hercules, CA, USA).
In vivo experiments
Tumors were established by injecting 1 Â 10 7 BxPC3 human pancreatic ductal adenocarcinoma cells suspended in 100 ml of PBS subcutaneously into right scapulas of 15 4-week-old Balb/c nude mice. Seven days later, the tumors were palpable, and mice were randomized into three groups (i.e. Smo antisense group, LacZ group and the no treatment group; n ¼ 5 in each group), and received intratumoral injections of Ad-ptch/p-SAS (10 9 plaque-forming unit), Ad-ptch/p-LacZ (10 9 plaqueforming unit) or PBS, respectively, daily for 5 days. Tumor volume was calculated according to the following formula: volume ¼ (width) 2 Â length/2. Animals were killed after 4 weeks, and tumors were excised and weighed. Tissues were dehydrated and embedded in paraffin; 5-mm sections were stained with H&E for histological and morphologic evaluation. The apoptotic bodies, whose cardinal features are a condensed, shrunken cytoplasm and prominent nuclear alteration, were observed in the tissue sections.
